Sanofi Completes Acquisition of Vicebio
Sanofi has completed the acquisition of Vicebio Ltd, enhancing its vaccine portfolio with an early-stage candidate for RSV and HMPV. This acquisition leverages Vicebio's Molecular Clamp technology, adding a non-mRNA option to Sanofi's respiratory vaccine pipeline, thus expanding choices for physicians and patients. The original content was published by Sanofi via GlobeNewswire on December 4, 2025.
Sanofi has completed the acquisition of Vicebio Ltd, bringing an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) into its portfolio. This move expands Sanofi’s capabilities in vaccine design and development, leveraging Vicebio’s Molecular Clamp technology. The acquired vaccine candidate complements Sanofi’s existing position in respiratory vaccines by adding a non-mRNA option to its pipeline, offering greater choice for physicians and patients in the fight against RSV and HMPV. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142899-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
